Although tumor PD-L1 expression could not be assessed in our control EGFR-mutated group due to a lack of available tumor samples, these information suggest that sPD-1 and sPD-L1 may play a part in resistance to anti-PD1 therapies in this specific population. Here, EGFR is linked to neoplasm.